• Home >>
  • Pharmaceuticals and Healthcare >>
  • Antibacterial Drugs Market : Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis and Competitive Analysis 2017 - 2025

Antibacterial Drugs Market : Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis and Competitive Analysis 2017 - 2025

ID: 58976 February, 2018 Region : Global Pages Reports Monitor

Global antibacterial drugs market, by drug class (quinolones, B-lactams, macrolides, tetracycline, sulphonamide and others), route of administration (oral, parenteral and others), end user (hospital, clinics and others) forecast till 2025
Market scenario

Antibacterial drugs are chemical substances which inhibit the growth of the bacterial or destroy them. Drug Substances produced from microbes are called antibiotics. The pipeline drugs in this market are Cadazoli, Ozenoxacin, Arikace, Carbavance, Eravacycline, Actoxumab.Globally anti-bacterial drug market is driven by demand of new broad spectrum drug molecule and rising incidence of antibiotic resistance.  Availability of different formulation in enteral and parenteral route of administration helps in patient compliance.


Encouragement by FDA to developed new anti-bacterial drug is one of the major drivers to grow the market. Rising incidence of infections, other diseases globally and increasing government support in R&D activities are some of the key factors for this market.  Growing number of antibiotic resistance is major issue at global level to restrains the market but at the same time it can be converted into opportunity to developed new molecule with broader spectrum. Low return on investment and expiry of patented drugs are two major challenges faced by this market.

Segmentation

The global anti-bacterial market is segmented on the basis of drug class, route of administration and end user.
On the basis of drug class, the market is segmented into quinolones, B-lactams, macrolides, tetracycline, sulphonamide and others.
On the basis of route of administration, the market is segmented into oral, parenteral and others.
On the basis of end user, the market is segmented into hospital, clinics and others.

Regional Analysis
North America Dominates the anti-bacterial drugs market in terms of revenue and expected to hold the position Followed by Europe region. Dominating position is attributes by high diagnosis and treatment rate. Asia-Pacific is anticipated to grow at higher rate due to increased in patient population and growing healthcare infrastructure. Rising research & development activities in developing countries led to become a lucrative market for anti-bacterial drugs.   


Key Players
The key players in the market are: Pfizer, Inc., Merck & Co., Inc. , GlaxoSmithKline plc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Sanofi, AstraZeneca plc and Bayer AG.

Segmentation
By Drug Class:
• Quinolones 
• B-lactams 
• Macrolides 
• Tetracycline 
• Sulphonamide 
• Others
By Route of Administration:
• Oral
• Parenteral
• Others
By End User:
• Hospitals
• Clinics
• Others


By Region:
• North America
• Europe
• Asia-Pacific
• LAMEA

Research Scope
The study for Global Antibacterial Drugs Market will provide market size, estimates and forecast based on the following years: 
 
Historic data: 2015  Base Year Estimate: 2016  Forecast: 2017 to 2025


The report has been categorized in two distinctive sections, where the first category titled as Market Overview provides a holistic view of the market, key trends, drivers, challenges/restraints or opportunities with their current and expected impact on the overall industry sales. 
Our analyst implement several qualitative tools such as Ansoff’s Matrix, PESTEL analysis, Porter’s five force analysis among other to interpret and represent key industry findings. 
The second section of the study provides market size, estimates and forecast for key market segments and regional market. The final part of the report highlights key manufacturers/vendors operating in the associated market. 


1. Introduction
1.1. Market Definition
1.2. Market Scope


2. Research Methodology
2.1. Primary Research
2.2. Secondary Sources
2.3. Assumptions & Exclusions


3. Market Overview
3.1. Research Report Segmentation & Scope
3.2. Key Market Trend Analysis
3.2.1. Market Drivers
3.2.2. Market Restraint/Challenges
3.2.3. Market Opportunities
3.3. Porter’s Five Forces Analysis
3.4. Potential Venture Avenues
3.5. Market Share Analysis, 2016 
3.6. Market Overview


4. Drug Class Overview
4.1. Introduction
4.2. Market Size & Forecast, 2015 to 2025
4.2.1. Quinolones 
4.2.2. B-lactams 
4.2.3. Macrolides 
4.2.4. Tetracycline 
4.2.5. Sulphonamide 
4.2.6. Others
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


5. Route of Administration Overview
5.1. Introduction
5.2. Market Size & Forecast, 2015 to 2025
5.2.1. Oral
5.2.2. Parenteral
5.2.3. Others
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


6. End User Overview
6.1. Introduction
6.2. Market Size & Forecast, 2015 to 2025
6.2.1. Hospitals
6.2.2. Clinics
6.2.3. Others
(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


7. Regional Overview
7.1. Introduction
7.2. Market Size & Forecast, 2015 to 2025
7.2.1. North America
7.2.1.1. U.S.
7.2.1.2. Canada
7.2.1.3. Mexico 
7.2.2. Europe
7.2.2.1. UK
7.2.2.2. Germany
7.2.2.3. France
7.2.2.4. Italy 
7.2.2.5. Spain
7.2.2.6. Rest of Europe
7.2.3. Asia-Pacific
7.2.3.1. China
7.2.3.2. India
7.2.3.3. Japan
7.2.3.4. South Korea
7.2.3.5. Rest of Asia-Pacific
7.2.4. LAMEA
7.2.4.1. Brazil
7.2.4.2. UAE
7.2.4.3. South Africa
7.2.4.4. Rest of LAMEA
(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


8. Manufacturer/ Vendor Profile
8.1. The following attributes will be considered while profiling key manufacturers in this industry: 
8.1.1. Company Overview
8.1.2. Financial Synopsis
8.1.3. Recent Developments
8.1.4. R&D Investments (if any)
8.1.5. Strategy Overview (Analyst Perspective)
8.1.6. Product Portfolio
8.2. Companies Profiled
8.2.1. Pfizer, Inc.
8.2.2. Merck & Co., Inc. 
8.2.3. GlaxoSmithKline plc. 
8.2.4. Novartis AG
8.2.5. Eli Lilly and Company
8.2.6. Johnson & Johnson
8.2.7. Sanofi
8.2.8. AstraZeneca plc
8.2.9. Bayer AG
 (Note: The companies mentioned above are tentative in nature, and profiles of other market players not listed here can be included on request.) 

Request Sample

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Request Discount

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Related Reports




Get 15 minutes of free Consultation When you request a Sample Report!

24/7 Research Report

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone:

+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected]